EGFR and metastatic colorectal cancer: In a phase Ib trial from the US by Subramaniam et al., the combination therapy of AUY922 with cetuximab (EGFR-antibody) applied in 16 patients with at least second line chemotherapy-refractory metastatic colorectal cancer showed a median OS of 37.2 weeks (95% CI 4.9–115.1 weeks) and a median PFS of 7.9 weeks (95% CI 5.9–29.9 weeks) (NCT01294826) (Subramaniam et al. 2015).